JAK2 (Tyrosine-protein kinase JAK2) variants and mutations
JAK2 (also known as Tyrosine-protein kinase JAK2) is a human protein-coding gene encoding a tyrosine-protein kinase protein. It transmits signals from erythropoietin, thrombopoietin, growth hormone, and other cytokine receptors into STAT-dependent transcription. The V617F gain-of-function variant is a major driver of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. This analysis covers 2,208 JAK2 variants and mutations. Of these, 80% have computational variant effect predictions. Disease context includes acquired polycythemia vera, primary myelofibrosis, and myelofibrosis. Example JAK2 variants include G2R, G2V, and G2A.
Variant analysis overview
- Gene: JAK2
- Protein: Tyrosine-protein kinase JAK2
- UniProt accession: O60674
- Organism: Homo sapiens
- Variants analyzed: 2208
- Variant scope: all variants
- Completed: 2026-08-18
Variant and mutation evidence
- Variant composition: 2,005 unspecified-consequence records; 105 missense variants; 79 synonymous variants; 8 frameshift variants; 6 stop-gained variants; 3 in-frame deletions; 2 splice-region variants
- Prediction scores: 1,769 variants have prediction scores (80% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: acquired polycythemia vera, primary myelofibrosis, myelofibrosis, ulcerative colitis, myeloproliferative disorder, Crohn disease, neoplasm, Splenomegaly, acute myeloid leukemia, cancer, essential thrombocythemia, thrombocythemia 3.
Protein structure and variant hotspots
- Protein features: 4 domains; 2 binding sites; 11 post-translational modification sites.
- Structural context: 1,885 variants have structural context.
- PTM context: 15 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable JAK2 variants
Examples include G2R, G2V, G2A, G2G, M3K, A4D, A4G, A4V. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- G2R (p.Gly2Arg), ExAC rs772421530, gnomAD rs772421530, REVEL 0.24, AlphaMissense 0.49
- G2V (p.Gly2Val), TOPMed rs1822462968, MetaLR 0.35, MetaSVM -0.68
- G2A (p.Gly2Ala), gnomAD 9-5021992-G-C, REVEL 0.22, AlphaMissense 0.11
- G2G (p.Gly2Gly), rs1311151192, gnomAD 9-5021993-A-C, CADD 11.00
- M3K (p.Met3Lys), gnomAD 9-5021995-T-A, REVEL 0.56, AlphaMissense 0.48
- A4D (p.Ala4Asp), ExAC rs773675185, TOPMed rs773675185, gnomAD rs773675185, REVEL 0.45, AlphaMissense 0.63
- A4G (p.Ala4Gly), ExAC rs773675185, TOPMed rs773675185, gnomAD rs773675185, REVEL 0.30, AlphaMissense 0.19
- A4V (p.Ala4Val), ExAC rs773675185, TOPMed rs773675185, gnomAD rs773675185, REVEL 0.37, AlphaMissense 0.64
- A4A (p.Ala4Ala), rs760970893, gnomAD 9-5021999-C-T, CADD 6.87
- C5F (p.Cys5Phe), Ensembl rs989395358, MetaLR 0.57, MetaSVM 0.18
- C5Y (p.Cys5Tyr), gnomAD 9-5022001-G-A, REVEL 0.52, AlphaMissense 0.31
- L6I (p.Leu6Ile), TOPMed rs939621043, MetaLR 0.60, MetaSVM 0.12
- L6L (p.Leu6Leu), rs1822463819, gnomAD 9-5022005-T-A, CADD 6.47
- T7M (p.Thr7Met), rs770579392, NCI-TCGA Cosmic COSV6769, ExAC rs770579392, TOPMed rs770579392, REVEL 0.18, AlphaMissense 0.11, Likely benign, not provided
- T7N (p.Thr7Asn), gnomAD 9-5022005-T-TA, CADD 25.30
- T7R (p.Thr7Arg), gnomAD 9-5022007-C-G, REVEL 0.42, AlphaMissense 0.20
- T7T (p.Thr7Thr), rs776155206, gnomAD 9-5022008-G-A, CADD 2.06
- M8I (p.Met8Ile), TOPMed rs1822464264, gnomAD rs1822464264, REVEL 0.30, AlphaMissense 0.31
- M8V (p.Met8Val), gnomAD 9-5022009-A-G, REVEL 0.14, AlphaMissense 0.07
- T9I (p.Thr9Ile), TOPMed rs1194427389, REVEL 0.40, AlphaMissense 0.30
- T9P (p.Thr9Pro), Ensembl rs2130074421, MetaLR 0.26, MetaSVM -0.74
- T9T (p.Thr9Thr), rs1822464540, gnomAD 9-5022014-A-G, CADD 7.42
- M11I (p.Met11Ile), TOPMed rs945180127, REVEL 0.28, AlphaMissense 0.33
- M11V (p.Met11Val), gnomAD 9-5022018-A-G, REVEL 0.38, AlphaMissense 0.12
- M11K (p.Met11Lys), gnomAD 9-5022019-T-A, REVEL 0.46, AlphaMissense 0.20
- E12K (p.Glu12Lys), NCI-TCGA TCGA novel, MetaLR 0.33, MetaSVM -0.43, Variant assessed as somatic; moderate impact.
- E12Q (p.Glu12Gln), NCI-TCGA TCGA novel, REVEL 0.35, AlphaMissense 0.12, Variant assessed as somatic; moderate impact.
- E12A (p.Glu12Ala), gnomAD 9-5022022-A-C, REVEL 0.44, AlphaMissense 0.12
- G13E (p.Gly13Glu), NCI-TCGA Cosmic COSV6766, REVEL 0.21, AlphaMissense 0.09, Variant assessed as somatic; moderate impact.
- G13R (p.Gly13Arg), Ensembl rs2130074528, MetaLR 0.30, MetaSVM -0.69
- G13V (p.Gly13Val), rs759031245, ClinGen CA4971469, ClinVar RCV003717850, ExAC rs759031245, REVEL 0.18, AlphaMissense 0.09, Likely benign, not provided
- T14A (p.Thr14Ala), TOPMed rs1822464904, REVEL 0.22, AlphaMissense 0.06
- T14I (p.Thr14Ile), ExAC rs764901971, gnomAD rs764901971, REVEL 0.27, AlphaMissense 0.09
- T14K (p.Thr14Lys), ExAC rs764901971, gnomAD rs764901971, MetaLR 0.36, MetaSVM -0.51
- T14T (p.Thr14Thr), gnomAD 9-5022029-A-T, CADD 3.45
- S15C (p.Ser15Cys), ExAC rs200322825, TOPMed rs200322825, gnomAD rs200322825
- S15F (p.Ser15Phe), ExAC rs200322825, TOPMed rs200322825, gnomAD rs200322825, REVEL 0.18, AlphaMissense 0.12, Uncertain significance, not provided
- S15P (p.Ser15Pro), gnomAD rs1266649645, REVEL 0.13, AlphaMissense 0.08
- S15Y (p.Ser15Tyr), gnomAD 9-5022031-C-A, REVEL 0.25, AlphaMissense 0.11
- S15S (p.Ser15Ser), rs763029603, gnomAD 9-5022032-C-T, CADD 2.77
- T16A (p.Thr16Ala), gnomAD rs1422678517, REVEL 0.20, AlphaMissense 0.06
- T16P (p.Thr16Pro), gnomAD 9-5022033-A-C, REVEL 0.28, AlphaMissense 0.06
- T16S (p.Thr16Ser), gnomAD 9-5022033-A-T, REVEL 0.20, AlphaMissense 0.07
- T16I (p.Thr16Ile), gnomAD 9-5022034-C-T, REVEL 0.17, AlphaMissense 0.09
- T16T (p.Thr16Thr), rs763955675, gnomAD 9-5022035-C-A, CADD 1.06
- S17F (p.Ser17Phe), gnomAD rs1168591378, REVEL 0.24, AlphaMissense 0.12
- S17Y (p.Ser17Tyr), gnomAD rs1168591378
- S17S (p.Ser17Ser), rs1256899616, gnomAD 9-5022038-T-G, CADD 6.32
- S18C (p.Ser18Cys), rs1351891082, NCI-TCGA Cosmic COSV6760, gnomAD rs1351891082, REVEL 0.37, AlphaMissense 0.07, Variant assessed as somatic; moderate impact.
- S18Y (p.Ser18Tyr), gnomAD rs1351891082
- S18F (p.Ser18Phe), gnomAD 9-5022040-C-T, REVEL 0.35, AlphaMissense 0.12
- S18S (p.Ser18Ser), gnomAD 9-5022041-T-C, CADD 4.98
- I19M (p.Ile19Met), gnomAD rs1302672595, REVEL 0.12, AlphaMissense 0.07
- I19V (p.Ile19Val), rs150159583, ClinGen CA4971475, ClinVar RCV003728937, ClinVar RCV004985562, REVEL 0.21, AlphaMissense 0.06, Conflicting interpretations, Inborn genetic diseases; not provided
- I19I (p.Ile19Ile), rs1302672595, gnomAD 9-5022044-A-T, CADD 0.91
- Y20D (p.Tyr20Asp), Ensembl rs906594522, REVEL 0.12, AlphaMissense 0.09
- Y20C (p.Tyr20Cys), gnomAD 9-5022046-A-G, REVEL 0.34, AlphaMissense 0.07
- Y20* (p.Tyr20Ter), gnomAD 9-5022047-T-G, CADD 34.00
- Q21H (p.Gln21His), TOPMed rs1319914611, gnomAD rs1319914611, REVEL 0.30, AlphaMissense 0.16
- Q21K (p.Gln21Lys), Ensembl rs2130074954, MetaLR 0.24, MetaSVM -0.75
- N22S (p.Asn22Ser), ExAC rs780253547, gnomAD rs780253547, REVEL 0.34, AlphaMissense 0.14
- N22T (p.Asn22Thr), ExAC rs780253547, gnomAD rs780253547, REVEL 0.36, AlphaMissense 0.19
- N22I (p.Asn22Ile), gnomAD 9-5022051-A-AT, CADD 27.00
- N22N (p.Asn22Asn), rs1822467315, gnomAD 9-5022053-T-C, CADD 8.66
- G23A (p.Gly23Ala), ExAC rs779030695, gnomAD rs779030695, REVEL 0.39, AlphaMissense 0.20
- G23S (p.Gly23Ser), ExAC rs755035784, gnomAD rs755035784, REVEL 0.28, AlphaMissense 0.16
- G23V (p.Gly23Val), gnomAD 9-5022053-TG-T, CADD 28.10
- D24N (p.Asp24Asn), gnomAD 9-5022057-G-A, REVEL 0.26, AlphaMissense 0.08
- D24G (p.Asp24Gly), gnomAD 9-5022058-A-G, REVEL 0.19, AlphaMissense 0.10
- I25T (p.Ile25Thr), gnomAD rs1339135099, REVEL 0.29, AlphaMissense 0.11
- S26F (p.Ser26Phe), ExAC rs748622306, TOPMed rs748622306, gnomAD rs748622306
- S26Y (p.Ser26Tyr), gnomAD 9-5022064-C-A, REVEL 0.26, AlphaMissense 0.09
- S26S (p.Ser26Ser), rs772519132, gnomAD 9-5022065-T-C, CADD 12.00
- N28S (p.Asn28Ser), TOPMed rs1232333083, gnomAD rs1232333083, REVEL 0.17, AlphaMissense 0.07
- N28I (p.Asn28Ile), gnomAD 9-5022070-A-T, REVEL 0.14, AlphaMissense 0.09
- A29G (p.Ala29Gly), TOPMed rs1321992857, gnomAD rs1321992857, REVEL 0.09, AlphaMissense 0.08, Uncertain significance
- A29T (p.Ala29Thr), Ensembl rs2130075244, MetaLR 0.15, MetaSVM -1.02
- A29V (p.Ala29Val), rs1321992857, ClinGen CA372819684, ClinVar RCV003703044, TOPMed rs1321992857, REVEL 0.10, AlphaMissense 0.08, Uncertain significance, not provided
- N30I (p.Asn30Ile), Ensembl rs2130075335, MetaLR 0.26, MetaSVM -0.90
- N30S (p.Asn30Ser), gnomAD 9-5022076-A-G, REVEL 0.09, AlphaMissense 0.06
- S31C (p.Ser31Cys), gnomAD 9-5022079-C-G, REVEL 0.22, AlphaMissense 0.07
- M32L (p.Met32Leu), ExAC rs778174935, TOPMed rs778174935, gnomAD rs778174935, MetaLR 0.15, MetaSVM -0.99, Uncertain significance
- M32V (p.Met32Val), rs778174935, ClinGen CA4971482, ClinVar RCV003337754, ClinVar RCV005061285, REVEL 0.22, AlphaMissense 0.05, Uncertain significance, not provided; Thrombocythemia 3
- K33M (p.Lys33Met), TOPMed rs538474116, gnomAD rs538474116, REVEL 0.39, AlphaMissense 0.17
- K33T (p.Lys33Thr), TOPMed rs538474116, gnomAD rs538474116, REVEL 0.19, AlphaMissense 0.12, Uncertain significance, not provided
- Q34R (p.Gln34Arg), gnomAD rs1194311101, REVEL 0.23, AlphaMissense 0.08
- Q34P (p.Gln34Pro), gnomAD 9-5022088-A-C, REVEL 0.22, AlphaMissense 0.06
- Q34Q (p.Gln34Gln), rs1822469167, gnomAD 9-5022089-A-G, CADD 5.42
- Q34H (p.Gln34His), gnomAD 9-5022089-A-T, REVEL 0.30, AlphaMissense 0.11
- I35R (p.Ile35Arg), ExAC rs761588246, TOPMed rs761588246, gnomAD rs761588246, REVEL 0.17, AlphaMissense 0.07, Uncertain significance
- I35T (p.Ile35Thr), rs761588246, ClinGen CA4971483, ClinVar RCV002603513, ExAC rs761588246, REVEL 0.09, AlphaMissense 0.05, Uncertain significance, not provided
- I35K (p.Ile35Lys), gnomAD 9-5022091-T-A, REVEL 0.14, AlphaMissense 0.09
- P37L (p.Pro37Leu), Ensembl rs748500115, REVEL 0.31, AlphaMissense 0.14
- P37P (p.Pro37Pro), rs1207337914, gnomAD 9-5022098-A-G, CADD 9.38
- V38F (p.Val38Phe), ExAC rs771216385, TOPMed rs771216385, gnomAD rs771216385, REVEL 0.13, AlphaMissense 0.10
- V38I (p.Val38Ile), ExAC rs771216385, TOPMed rs771216385, gnomAD rs771216385
- V38L (p.Val38Leu), ExAC rs771216385, TOPMed rs771216385, gnomAD rs771216385, MetaLR 0.24, MetaSVM -0.94
- L39F (p.Leu39Phe), Ensembl rs1822469952, REVEL 0.54, AlphaMissense 0.23
- L39V (p.Leu39Val), gnomAD 9-5022102-C-G, REVEL 0.48, AlphaMissense 0.22
- Q40* (p.Gln40Ter), gnomAD rs1183427218, CADD 36.00
- Q40H (p.Gln40His), gnomAD rs1416185810, REVEL 0.16, AlphaMissense 0.14
- Q40P (p.Gln40Pro), gnomAD 9-5022106-A-C, REVEL 0.52, AlphaMissense 0.58
- Q40R (p.Gln40Arg), gnomAD 9-5022106-A-G, REVEL 0.23, AlphaMissense 0.07
- Q40Q (p.Gln40Gln), gnomAD 9-5022107-G-A, CADD 5.90
- V41V (p.Val41Val), rs776336648, gnomAD 9-5022110-G-T, CADD 6.09
- Y42* (p.Tyr42Ter), ESP rs369748023
- L43F (p.Leu43Phe), TOPMed rs1822470695, gnomAD rs1822470695, REVEL 0.24, AlphaMissense 0.18
- Y44* (p.Tyr44Ter), NCI-TCGA Cosmic COSV6761, CADD 35.00, Variant assessed as somatic; high impact.
- Y44C (p.Tyr44Cys), NCI-TCGA TCGA novel, MetaLR 0.69, MetaSVM 0.48, Variant assessed as somatic; moderate impact.
- Y44Y (p.Tyr44Tyr), rs759331856, gnomAD 9-5022119-C-T, CADD 6.71
- H45N (p.His45Asn), Ensembl rs2130075817, MetaLR 0.36, MetaSVM -0.57
- S46Y (p.Ser46Tyr), rs138655335, ClinGen CA4971487, ClinVar RCV002621061, ClinVar RCV002643708, REVEL 0.23, AlphaMissense 0.14, Conflicting interpretations, Inborn genetic diseases; not provided
- S46S (p.Ser46Ser), rs1481240014, gnomAD 9-5022125-C-T, CADD 6.72
- L47I (p.Leu47Ile), gnomAD 9-5022126-C-A, REVEL 0.17, AlphaMissense 0.07
- L47L (p.Leu47Leu), rs149333413, gnomAD 9-5022128-T-A, CADD 9.23
- G48E (p.Gly48Glu), rs143227399, ClinGen CA4971490, ClinVar RCV001794992, ClinVar RCV001822010, REVEL 0.02, AlphaMissense 0.09, Conflicting interpretations, not specified; not provided
- G48R (p.Gly48Arg), ExAC rs762570559, gnomAD rs762570559, REVEL 0.21, AlphaMissense 0.14
- G48G (p.Gly48Gly), gnomAD 9-5022131-G-A, CADD 8.35
- K49K (p.Lys49Lys), rs774158685, gnomAD 9-5022134-A-G, CADD 7.27
- S50Y (p.Ser50Tyr), Ensembl rs2130075995
- S50T (p.Ser50Thr), gnomAD 9-5022135-T-A, REVEL 0.09, AlphaMissense 0.06
- E51D (p.Glu51Asp), TOPMed rs767076792, gnomAD rs767076792, MetaLR 0.06, MetaSVM -1.10
- E51E (p.Glu51Glu), rs767076792, gnomAD 9-5022140-G-A, CADD 0.63
- A52E (p.Ala52Glu), TOPMed rs1822472204, gnomAD rs1822472204, MetaLR 0.08, MetaSVM -1.10
- A52T (p.Ala52Thr), rs369833874, ESP rs369833874, TOPMed rs369833874, REVEL 0.12, AlphaMissense 0.07, Variant assessed as somatic; moderate impact.
- A52V (p.Ala52Val), TOPMed rs1822472204, gnomAD rs1822472204, REVEL 0.07, AlphaMissense 0.09
- A52G (p.Ala52Gly), gnomAD 9-5022142-C-G, REVEL 0.06, AlphaMissense 0.05
- A52A (p.Ala52Ala), rs1822472342, gnomAD 9-5022143-A-G, CADD 8.84
- D53A (p.Asp53Ala), NCI-TCGA Cosmic COSV6757, MetaLR 0.15, MetaSVM -0.95, Variant assessed as somatic; moderate impact.
- D53Y (p.Asp53Tyr), ExAC rs761608925, gnomAD rs761608925, REVEL 0.14, AlphaMissense 0.14
- Y54F (p.Tyr54Phe), Ensembl rs1325660414, REVEL 0.29, AlphaMissense 0.07
- Y54C (p.Tyr54Cys), gnomAD 9-5022148-A-G, REVEL 0.28, AlphaMissense 0.07
- Y54Y (p.Tyr54Tyr), gnomAD 9-5022149-T-C, CADD 3.23
- L55P (p.Leu55Pro), NCI-TCGA Cosmic COSV6759, REVEL 0.60, AlphaMissense 0.90, Variant assessed as somatic; moderate impact.
- L55Q (p.Leu55Gln), TOPMed rs1822472748, MetaLR 0.27, MetaSVM -0.54
- L55L (p.Leu55Leu), rs1379385626, gnomAD 9-5022152-G-A, CADD 1.57
- T56N (p.Thr56Asn), gnomAD 9-5022154-C-A, REVEL 0.03, AlphaMissense 0.08
- T56S (p.Thr56Ser), gnomAD 9-5022154-C-G, REVEL 0.04, AlphaMissense 0.08
- T56T (p.Thr56Thr), gnomAD 9-5022155-C-G, CADD 0.91
- F57L (p.Phe57Leu), ExAC rs767273014, TOPMed rs767273014, gnomAD rs767273014, REVEL 0.13, AlphaMissense 0.88
- F57F (p.Phe57Phe), gnomAD 9-5022158-T-C, CADD 6.68
- P58H (p.Pro58His), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- P58Q (p.Pro58Gln), Ensembl rs2130076287, REVEL 0.16, AlphaMissense 0.10
- P58S (p.Pro58Ser), Ensembl rs2130076246, MetaLR 0.12, MetaSVM -1.01
- P58A (p.Pro58Ala), gnomAD 9-5022159-C-G, REVEL 0.14, AlphaMissense 0.08
- P58T (p.Pro58Thr), gnomAD 9-5022159-C-A, REVEL 0.12, AlphaMissense 0.09
- P58L (p.Pro58Leu), gnomAD 9-5022160-C-T, REVEL 0.10, AlphaMissense 0.10
- P58P (p.Pro58Pro), gnomAD 9-5022161-A-G, CADD 7.92
- S59A (p.Ser59Ala), gnomAD rs1312201445, REVEL 0.01, AlphaMissense 0.05
- S59C (p.Ser59Cys), rs754086152, ClinGen CA4971495, ClinVar RCV001822470, ClinVar RCV004988770, REVEL 0.02, AlphaMissense 0.07, Uncertain significance, not specified; Inborn genetic diseases
- S59F (p.Ser59Phe), rs754086152, ClinGen CA4971494, ClinVar RCV003344698, ExAC rs754086152, REVEL 0.05, AlphaMissense 0.12, Uncertain significance, Inborn genetic diseases
- S59P (p.Ser59Pro), gnomAD rs1312201445, MetaLR 0.03, MetaSVM -1.00
- G60E (p.Gly60Glu), Ensembl rs2130076403
- G60V (p.Gly60Val), Ensembl rs2130076403, MetaLR 0.33, MetaSVM -0.39
- G60A (p.Gly60Ala), gnomAD 9-5022166-G-C, REVEL 0.28, AlphaMissense 0.32
- E61K (p.Glu61Lys), rs1439413818, ClinGen CA372819889, ClinVar RCV002308886, TOPMed rs1439413818, REVEL 0.08, AlphaMissense 0.09, Uncertain significance, not provided
- E61Q (p.Glu61Gln), gnomAD 9-5022168-G-C, REVEL 0.07, AlphaMissense 0.10
- E61E (p.Glu61Glu), rs765467595, gnomAD 9-5022170-G-A, CADD 5.93
- E61D (p.Glu61Asp), gnomAD 9-5022170-G-C, REVEL 0.04, AlphaMissense 0.09
- Y62C (p.Tyr62Cys), ESP rs139087749, ExAC rs139087749, TOPMed rs139087749, gnomAD rs139087749, REVEL 0.41, AlphaMissense 0.31
- Y62H (p.Tyr62His), gnomAD 9-5022171-T-C, REVEL 0.24, AlphaMissense 0.34
- V63A (p.Val63Ala), rs1211921813, ClinGen CA372819907, ClinVar RCV003856654, TOPMed rs1211921813, REVEL 0.11, AlphaMissense 0.17, Uncertain significance, not provided
- V63I (p.Val63Ile), ExAC rs758479739, gnomAD rs758479739, REVEL 0.11, AlphaMissense 0.08
- A64T (p.Ala64Thr), Ensembl rs2130076565, MetaLR 0.12, MetaSVM -1.02
- A64V (p.Ala64Val), gnomAD 9-5022178-C-T, REVEL 0.21, AlphaMissense 0.38
- A64A (p.Ala64Ala), rs778287602, gnomAD 9-5022179-A-G, CADD 10.30
- E65Q (p.Glu65Gln), ExAC rs773146013, TOPMed rs773146013, gnomAD rs773146013, REVEL 0.28, AlphaMissense 0.75
- E65K (p.Glu65Lys), gnomAD 9-5022180-G-A, REVEL 0.46, AlphaMissense 0.87
- E66* (p.Glu66Ter), NCI-TCGA Cosmic COSV6765, Variant assessed as somatic; high impact.
- E66A (p.Glu66Ala), ExAC rs757639029, gnomAD rs757639029, REVEL 0.65, AlphaMissense 0.24
- E66K (p.Glu66Lys), gnomAD rs1183227511, MetaLR 0.44, MetaSVM -0.38
- E66Q (p.Glu66Gln), gnomAD rs1183227511, REVEL 0.38, AlphaMissense 0.17
- I67M (p.Ile67Met), NCI-TCGA Cosmic COSV6761, Variant assessed as somatic; moderate impact.
- I67N (p.Ile67Asn), Ensembl rs1822475200
- I67V (p.Ile67Val), Ensembl rs1822475055, MetaLR 0.05, MetaSVM -1.09
- I67I (p.Ile67Ile), rs1822475350, gnomAD 9-5022188-C-A, CADD 8.17
- p.Cys68 Ile69delinsPhe, gnomAD 9-5022189-TGTA-T, CADD 19.70
- C68C (p.Cys68Cys), rs1822475502, gnomAD 9-5022191-T-C, CADD 13.00
- I69M (p.Ile69Met), gnomAD rs1159373106, REVEL 0.21, AlphaMissense 0.11
- I69T (p.Ile69Thr), gnomAD rs1441596935, REVEL 0.26, AlphaMissense 0.12
Public JAK2 analysis runs
- JAK2 analysis run — JAK2 (2,208 variants) — completed 2026-08-18